PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
From:
Published online 2008 March 28. doi: 10.1186/1471-2407-8-82

Table 2

Characteristics of 6 randomized trials comparing gemcitabine to gemcitabine plus fluoropyrimidine

ReferenceYearnTreatment regimenStage IV (%)Male (%)PS 0–1 (%)
Berlin2002162Gem 1000 mg/m2 for 3 of 4 wks905486
160Gem 1000 mg/m2 + 5-FU 600 mg/m2 for 3 of 4 wks895286
Riess2005238Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks775448*
235Gem 1000 mg/m2 + FA 200 mg/m2 5-FU 750 mg/m2 CI × 4 wks q 6 wks775244*
DiCostanzo200548Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks734869
43Gem 1000 mg/m2 + CI 5-FU 200 mg/m2 for 6 of 7 wks, then wkly for 3 of 4 wks676367
Scheithauer200342Gem 2200 mg/m2 q 2 wks1005524
41Gem 2200 mg/m2 + Capecitabine 2500 mg/m2 d1-7 q 2 wks1006627
Herrmann2005159Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks795353*
160Gem 1000 mg/m2 d1, 8 + Capecitabine 2 × 650 mg/m2 d1-14 q 3 wks805453*
Cunningham2005266Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks71na82
267Gem 1000 mg/m2 d1, 8, 15 + Capecitabine 2 × 830 mg/m2 d1-21 q 4 wks70na81

* KPS = 90–100%; PS = performance status; na = data not available;